London, UK-headquartered Evaluate, a company providing software services for researchers and drug developers, has released Product Specific PTRS (probability of technical and regulatory success), a platform which processes data to predict a drug’s probability of success.
According to the company, the product identifies ‘the exact attributes’ that are improving or degrading the risk profile of a product in every stage of the development process, and ranks these attributes in order of importance.
The platform covers data and insights from all new molecular entity (NME) and new drug applications (NDA) and uses machine learning to analyze over 50 drug, company, and market attributes as well as more than 30,000 phase transitions.
Product Specific PTRS is integrated with EvaluatePharma Vision, the company’s subscription service which provides data including the net present value, R&D costs, clinical timelines, and sales forecasts.
The platform is expected to support companies managing clinical portfolios “in light of rising development costs and increased pricing concerns,” said Deborah Kobewka, CEO of Evaluate.
According to Kobewka, only 51% of clinical products in Phase III obtain FDA approval, and, due to the significant costs of development programs and clinical studies, “drugmakers are under more pressure than ever to make sound, evidence-based decisions on how to invest in their pipelines.”